Experts provided insights into how precision medicine is being used to address the needs and care of patients with systemic sclerosis.
Systemic Lupus Erythematosus: A Complex, Multi-Challenging Disease
Reviewing the research presented at ACR Convergence 2024.
Can Cultural Humility Conquer Systemic Inequity in Pediatric Rheumatology?
Doctors and patient advocates urged the rheumatology community to address the drastic inadequacies in care faced by marginalized people in a session held at ACR Convergence 2024.
Collaborative Care Essential for Diagnosis & Care of Neurosarcoidosis
At a ACR Convergence 2024 session, experts discussed key characteristics, diagnostic challenges & treatment considerations for neurosarcoidosis.
Toward Personalized Medicine in Pediatric Lupus
At this ACR Convergence 2024 session, discussion centered on novel techniques that offer hope for developing personalized therapies for pediatric SLE.
Initiative Trains Clinicians About RA for the Navajo Community
The Rheumatology Access Expansion Initiative helps meet the needs of patients with rheumatoid arthritis in an underserved community in the U.S.
Lung Cancer in RA & RA-ILD
Brooks et al. evaluated the risk of lung cancer in patients with rheumatoid arthritis (RA) and RA-associated interstitial lung disease (ILD) compared with the risk in matched controls without RA or RA-ILD. Understanding whether RA predisposes someone to lung cancer and whether patients with RA-ILD represent a uniquely high-risk group could inform cancer-screening strategies.
Lupus Nephritis Guideline Encourages Triple Therapy
Screening recommendations, triple therapy and more—here are insights into the upcoming ACR guideline for the care and treatment of patients with lupus nephritis.
Top Research in Gout from ACR Convergence 2024 at a Glance
Dr. Lisa Stamp helps filter the noise to get to the key insights from the research abstracts on gout presented at ACR Convergence 2024.
The Great Pediatric Debate 2024: Cessation or Continuation of Biologics in sJIA Lung Disease?
Washington D.C.—At a Sunday, Nov. 17, Pediatrics Great Debate session of ACR Convergence, speakers argued whether patients with systemic juvenile idiopathic arthritis (sJIA) should continue their interleukin (IL) 1/IL-6 biologics if lung disease is suspected. Randy Q. Cron, MD, PhD, the director of the Division of Pediatric Rheumatology at the University of Alabama at Birmingham,…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 337
- Next Page »